Exabis Library
Welcome to the e-CCO Library!
P680: Similar gut bacterial composition between patients with ulcerative colitis and healthy controls in a high prevalence population: a cross-sectional study of the Faroe Islands IBD cohort
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P681 Efficacy of vedolizumab for the prevention of postoperative recurrence in Crohn’s disease: Data from clinical practice from the ENEIDA registry
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P681: Assessing internet based information used to aid patient decision making in surgery for perianal Crohn's fistula
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P681: Effectiveness and safety of oral Tacrolimus salvage therapy for acute severe ulcerative colitis: a retrospective study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P681: Higher in vitro mucin degradation, but no increased paracellular permeability by faecal water from Crohn’s disease patients
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P681: Impact of Crohn’s disease on survival in Korean patients with small bowel adenocarcinoma
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P681: Systematic review and meta-analysis of the safety and efficacy of intra-fistular injections of mesenchymal stem cells in clinical trials and observational cohort studies
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P681: Ustekinumab therapy induced clinically meaningful improvement and remission as measured by the Inflammatory Bowel Disease Questionnaire: Results from the phase 3 UNIFI induction and maintenance studies
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P682 Faecal calprotectin and C-reactive protein levels are associated with long-term clinical and endoscopic outcomes: Analysis of the OASIS open-label extension trial of etrasimod for ulcerative colitis
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P682: Antibiotic resistome profiles of fecal Escherichia coli isolates in association with Crohn’s disease
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P682: Development of anti-ustekinumab antibodies is an independent factor associated to loss of response to ustekinumab therapy in IBD patients
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P682: GO-CARE: a prospective multi-centre observational study of golimumab effectiveness and quality of life in a real life UC patient population in Italy
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P682: Predictors of response to biologics in Ulcerative Colitis: A population-based study from the epi-IIRN
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P682: Risk factors and clinical outcome in IBD patients with melanoma
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P682: Role of laboratory markers in paediatric inflammatory bowel disease
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P683 Infliximab, adalimumab and vedolizumab levels are not altered by pregnancy progression in IBD patients and neonatal vedolizumab levels are lower than in mothers: Results from the PICCOLO study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P683: Discontinuation of infliximab treatment: a comparison between IBD patients who retransitioned to originator and those who remained on biosimilar
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P683: Higher serum golimumab concentrations are significantly associated with combined clinical-biochemical remission during maintenance therapy: results from the GO-LEVEL study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P683: Leishmania infantum asymptomatic infection in inflammatory bowel disease patients under anti-TNF-α treatment
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P683: Maintenance of deep remission in patients with ulcerative colitis treated with thiopurines after withdrawal of the drug: Perspective real-life experience of a single centre
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM